Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaxis Ltd ( (AU:SNT) ) has shared an update.
Pharmaxis Ltd has announced interim results for its SNT-5505 product, which will be presented at the European Hematology Association Congress 2025. The final data is expected to be available in the second half of 2025, and while interim results provide insight, they may not definitively indicate the final outcomes of the trial.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.25 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 8,136,081
Technical Sentiment Signal: Buy
Current Market Cap: A$112.1M
Learn more about SNT stock on TipRanks’ Stock Analysis page.